West Oak Capital’s ImmunityBio IBRX Stock Holding History

West Oak Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,500	Closed	-$9.48K	–	319
2024 Q2	$9.48K	Hold	1,500	–	–	﹤0.01%	256
2024 Q1	$8K	Hold	1,500	–	–	﹤0.01%	258
2023 Q4	$6K	Hold	1,500	–	–	﹤0.01%	264
2023 Q3	$3K	Hold	1,500	–	–	﹤0.01%	277
2023 Q2	$4.17K	Hold	1,500	–	–	﹤0.01%	280
2023 Q1	$2.73K	Buy	+1,500	New	+$4.66K	﹤0.01%	286
2022 Q4	–	Sell	-1,500	Closed	-$7K	–	302
2022 Q3	$7K	Hold	1,500	–	–	﹤0.01%	260
2022 Q2	$6K	Hold	1,500	–	–	﹤0.01%	266
2022 Q1	$8K	Hold	1,500	–	–	﹤0.01%	277
2021 Q4	$9K	Hold	1,500	–	–	﹤0.01%	275
2021 Q3	$15K	Hold	1,500	–	–	0.01%	259
2021 Q2	$21K	Hold	1,500	–	–	0.01%	235
2021 Q1	$36K	Sell	1,500 -120	-7%	-$3.11K	0.02%	200
2020 Q4	$22K	Hold	1,620	–	–	0.01%	214
2020 Q3	$11K	Sell	1,620 -1,047	-39%	-$10.4K	0.01%	232
2020 Q2	$33K	Hold	2,667	–	–	0.02%	184
2020 Q1	$8K	Buy	+2,667	New	+$13.4K	0.01%	230

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

West Oak Capital's IBRX Position: Q3 2024 in Review

West Oak Capital sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 1,500 shares — an estimated $9.48K sold.

West Oak Capital first reported a position in IBRX in Q1 2020 and held it in 17 quarters. The position peaked at $36K in Q1 2021. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

West Oak Capital reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
West Oak Capital sold 1,500 ImmunityBio shares in Q3 2024, an estimated $9.48K.
West Oak Capital first reported a position in ImmunityBio in Q1 2020 and held it in 17 quarters.
West Oak Capital's ImmunityBio position peaked at $36K in Q1 2021.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on West Oak Capital's 13F filing for Q3 2024, filed 18 Oct 2024.